UBS Group’s GALENA BIOPHARMA INC COM RXII Stock Holding History

UBS Group’s Portfolio RXII Stock Details RXII Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,300	Closed	–	–	8437
2016 Q3	$0	Sell	1,300 -59,373	-98%	–	﹤0.01%	8363
2016 Q2	$28K	Buy	60,673 +39,373	+185%	+$18.2K	﹤0.01%	6026
2016 Q1	$29K	Buy	21,300 +10,331	+94%	+$14.1K	﹤0.01%	5932
2015 Q4	$16K	Buy	10,969 +333	+3%	+$486	﹤0.01%	6986
2015 Q3	$17K	Sell	10,636 -14,067	-57%	-$22.5K	﹤0.01%	6886
2015 Q2	$42K	Buy	24,703 +18,103	+274%	+$30.8K	﹤0.01%	6164
2015 Q1	$9K	Sell	6,600 -51,576	-89%	-$70.3K	﹤0.01%	7782
2014 Q4	$88K	Buy	+58,176	New	+$88K	﹤0.01%	5836

UBS Group's RXII Position: Q4 2016 in Review

UBS Group sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 1,300 shares.

UBS Group first reported a position in RXII in Q4 2014 and held it in 8 quarters. The position peaked at $88K in Q4 2014. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.

UBS Group reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
UBS Group sold 1,300 GALENA BIOPHARMA INC COM shares in Q4 2016.
UBS Group first reported a position in GALENA BIOPHARMA INC COM in Q4 2014 and held it in 8 quarters.
UBS Group's GALENA BIOPHARMA INC COM position peaked at $88K in Q4 2014.
0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.

Based on UBS Group's 13F filing for Q4 2016, filed 14 Feb 2017.